Breaking News Instant updates and real-time market news.

TEL

TE Connectivity

$62.52

-0.235 (-0.37%)

, FB

Facebook

$128.88

-1.36 (-1.04%)

12:03
10/12/16
10/12
12:03
10/12/16
12:03

TE SubCom, Facebook, Google, PLDC to build PLCN submarine cable network

TE SubCom, a TE Connectivity (TEL) company and an industry pioneer in undersea communications technology, along with Facebook (FB), Google (GOOG), and Pacific Light Data Communication , or PLDC, announced that they will co-build the Pacific Light Cable Network, or PLCN, a 12,800 km transpacific submarine cable system that will provide the first direct undersea route between Hong Kong and Los Angeles, California with ultra-high capacity transmission. Scheduled for commercial launch in summer of 2018, PLCN will include TE SubCom's C+L technology, a major step forward in available cable transmission capacity that effectively doubles the available bandwidth and capacity per fiber pair over a traditional C-band-only designed system. Once completed, PLCN will be the highest-capacity transpacific route.

TEL

TE Connectivity

$62.52

-0.235 (-0.37%)

FB

Facebook

$128.88

-1.36 (-1.04%)

GOOG

Alphabet

$783.07

-2.87 (-0.37%)

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 02

    Nov

  • 10

    Nov

  • 14

    Nov

  • 17

    Nov

  • 15

    Jan

TEL TE Connectivity
$62.52

-0.235 (-0.37%)

02/08/16
RBCM
02/08/16
NO CHANGE
RBCM
TE Connectivity CFO change should be manageable, says RBC Capital
After TE Connectivity said its CFO left the company to move to the Midwest, RBC Capital says it thinks the explanation "makes sense." The firm does not think the CFO's departure was related to business conditions or disagreements with the company. RBC adds that the company has strong remaining financial personnel, and it keeps a $65 price target and Outperform rating on the shares.
03/29/16
RHCO
03/29/16
DOWNGRADE
RHCO
Neutral
TE Connectivity downgraded to Neutral from Buy at SunTrust
05/09/16
GSCO
05/09/16
DOWNGRADE
Target $60
GSCO
Neutral
TE Connectivity downgraded to Neutral from Buy at Goldman
Goldman Sachs analyst Mark Delaney downgraded TE Connectivity to Neutral saying he sees greater upside to other stocks in the space. Delaney this morning upgraded CommScope (COMM) to Buy. He keeps a $66 price target for TE Connectivity shares.
08/04/16
MONN
08/04/16
UPGRADE
MONN
Buy
Innospec upgraded to Buy from Neutral at Monness Crespi
Monness Crespi upgraded Innospec to Buy and established a $60 price target saying it now sees much higher earnings for 2017 and beyond due to the acquisition of Huntsman's Personal Care surfactants business in Europe and indications by its sole customer, TE Connectivity (TEL), will continue to need product through 2017.
FB Facebook
$128.88

-1.36 (-1.04%)

10/04/16
PIPR
10/04/16
NO CHANGE
Target $185
PIPR
Overweight
Facebook issues at Marketplace launch a 'non-event,' says Piper Jaffray
Piper Jaffray analyst Gene Munster noted that after Facebook launched its new Marketplace offering on Monday that some users listed prohibited items, such as guns and drugs, that were not caught as they should have been by the company's filter. However, he views the misstep at launch as a "non-event" and thinks nothing has changed in term of Facebook's ability to build world-class products and go after new markets. Munster keeps an Overweight rating and $185 price target on Facebook shares.
10/10/16
WELS
10/10/16
NO CHANGE
WELS
Alphabet, Facebook can meet Street estimates, says Wells Fargo
Wells Fargo says that investors are concerned about the ability of Facebook (FB) and Google (GOOG,GOOGL) to meet Street estimates because forecasts continue to indicate that TV's ad share will be relatively stable over the next two years. But Wells says that Facebook and Google will continue to gain share from "non-TV media" and could see increased revenue from "non-advertising marketing services" such as sponsorships and public relations. Wells keeps Outperform ratings on both stocks.
10/11/16
NEED
10/11/16
NO CHANGE
Target $150
NEED
Buy
Needham raising Facebook estimates ahead of results
Needham analyst Laura Martin is raising her Facebook estimates for Q3 as she increases her estimates for Ad revenue going forward based on the company's increased number of advertisers using its platform, and her belief that ad growth will continue to realize robust performance for at least the next 12 to 18 months. The analyst reiterates a Buy rating and $150 price target on the shares.
10/03/16
BOFA
10/03/16
NO CHANGE
Target $150
BOFA
Buy
BofA/Merrill remains positive on Facebook heading into Q3 report
BofA/Merrill remains positive on Facebook heading into the Q3 report based on strong engagement, pricing tailwinds, and advertiser growth. The firm's analyst rate shares a Buy with a $150 price target and sees potential for a Q3 beat.
GOOG Alphabet
$783.07

-2.87 (-0.37%)

10/06/16
SBSH
10/06/16
NO CHANGE
Target $89
SBSH
Buy
Citi says Salesforce buying Twitter 'nearly impossible' above $28/share
Citi analyst Walter Pritchard believes a Salesforce (CRM) acquisition of Twitter (TWTR) is possible financially but that such a deal would put "significant constraints" on the company for the next three-plus years. The analyst sees "very little reason" for Salesforce to own Twitter and feels the acquisition "would pose a difficult decision" for CEO Marc Benioff and the board. Salesforce closed yesterday down 6%, or $4.21, to $68.42. Recode reported last night that the company is likely the only bidder left for Twitter after Disney (DIS) and Alphabet (GOOG) opted not to pursue a deal while Apple (AAPL) is unlikely. Twitter in pre-market trading is down 14% to $21.50. In order for Salesforce to avoid a shareholder vote, it would have to borrow $7.5B to fund the transaction if Twitter were valued at $20B, or $27.50-$28 per share, Pritchard tells investors in a research note. This is a level that likely constrains the company with little additional borrowing capacity for other deals, the analyst contends. He thinks the deal is "nearly impossible to do" for Salesforce should the bidding for Twitter go above $20B or $28 per share. Pritchard has a Buy rating on Salesforce with an $89 price target.
10/12/16
WELS
10/12/16
NO CHANGE
WELS
Market Perform
Wells doesn't see Apple as biggest beneficiary from Samsung issues
Wells Fargo analyst Maynard Um attributes the recent rally in shares of Apple (AAPL), at least in part, to Samsung's (SSNLF) issues with its Note 7 phones. Apple gained an incremental $14B in market capitalization at its intraday peak, which the analyst believes embeds more than 3M of incremental iPhone 7 Plus units. Samsung's production halt will help Apple, but other Android vendors with 5.7 inch phones could see a bigger benefit if Android users prefer to stick with Android, Um tells investors in a research note. He points out that LG, Kyocera, and Microsoft (MFST) have 5.7 inch Android phones at U.S. carriers. Um thinks expectations for Apple into earnings "have risen materially." He keeps a Market Perform rating on the iPhone maker. Apple closed yesterday up 25c to $116.30.
09/28/16
09/28/16
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alphabet (GOOG, GOOGL) downgraded to Underperform from Neutral at Wedbush with analyst James Dix citing concerns that the "Four Horsemen of the Search Apocalypse" -- self-identified consumers, consumer control of IP-delivered ads, payments innovation, and attention markets -- might arrive. 2. AT&T (T) downgraded to Neutral from Buy at UBS with analyst John Hodulik citing expectations for lower earnings growth. 3. Macy's (M) downgraded to Neutral from Outperform at Credit Suisse with analyst Michael Exstein saying the retailer, after outlining in August its operations and merchandising strategies, is now in an execution phase. 4. Twitter (TWTR) downgraded to Underperform from Neutral at Mizuho and to Sell from Hold at Loop Capital. 5. Galectin Therapeutics (GALT) downgraded to Sell from Buy at Roth Capital with analyst Sa'ar Yaniv citing the company's announcement that NASH-FX, GR-MD-02's Phase 2a study in NASH fibrosis, failed both primary and secondary endpoints. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:56
02/22/17
02/22
07:56
02/22/17
07:56
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Restaurant Brands…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

ARGS

Argos Therapeutics

$4.40

-0.3 (-6.38%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Hot Stocks
Breaking Hot Stocks news story on Argos Therapeutics »

Argos Therapeutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 27

    Apr

GS

Goldman Sachs

$251.76

1.38 (0.55%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Initiation
Goldman Sachs initiated  »

Goldman Sachs initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Mar

RDS.A

Royal Dutch Shell

$52.49

0.29 (0.56%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
Royal Dutch Shell to hold a conference call »

EVP of Gas and Energy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ACRX

AcelRx

$3.15

0.05 (1.61%)

, CBM

Cambrex

$54.90

0.55 (1.01%)

07:55
02/22/17
02/22
07:55
02/22/17
07:55
Conference/Events
RBC Capital to hold a conference »

Global Healthcare…

ACRX

AcelRx

$3.15

0.05 (1.61%)

CBM

Cambrex

$54.90

0.55 (1.01%)

CRIS

Curis

$2.66

-0.02 (-0.75%)

ESPR

Esperion

$24.42

-0.58 (-2.32%)

DVAX

Dynavax

$3.95

-0.05 (-1.25%)

FLXN

Flexion

$19.66

0.43 (2.24%)

GILD

Gilead

$69.29

-0.56 (-0.80%)

CURE

Curative Health Services Inc

$33.80

0.45 (1.35%)

PCRX

Pacira

$44.15

0.45 (1.03%)

NVDQ

Novadaq

$6.76

0.17 (2.58%)

AXON

Axovant Sciences

$12.11

-0.03 (-0.25%)

TSRO

TESARO

$190.27

-0.09 (-0.05%)

EGRX

Eagle Pharmaceuticals

$73.59

-0.53 (-0.72%)

LPNT

LifePoint

$65.15

1.25 (1.96%)

PRTA

Prothena

$55.00

-0.22 (-0.40%)

ABEO

Abeona Therapeutics

$5.25

-0.75 (-12.50%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

  • 23

    Feb

  • 28

    Feb

  • 28

    Feb

  • 28

    Feb

  • 01

    Mar

  • 01

    Mar

  • 02

    Mar

  • 06

    Mar

  • 17

    Mar

  • 21

    Mar

  • 01

    Apr

  • 27

    Apr

  • 30

    Jun

  • 06

    Oct

MS

Morgan Stanley

$46.56

0.41 (0.89%)

07:54
02/22/17
02/22
07:54
02/22/17
07:54
Initiation
Morgan Stanley initiated  »

Morgan Stanley initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:53
02/22/17
02/22
07:53
02/22/17
07:53
Conference/Events
Forecasters Club of New York to hold a luncheon meeting »

Federal Reserve Governor…

USPH

U.S. Physical Therapy

$76.10

2 (2.70%)

07:52
02/22/17
02/22
07:52
02/22/17
07:52
Conference/Events
CFA Society of Houston to hold a luncheon meeting »

Chris Reading, CEO of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 21

    Mar

  • 29

    Mar

  • 11

    Apr

  • 12

    Apr

SOHO

Sotherly Hotels

$7.04

-0.4 (-5.38%)

07:51
02/22/17
02/22
07:51
02/22/17
07:51
Recommendations
Sotherly Hotels analyst commentary  »

Sotherly Hotels can still…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GKOS

Glaukos

$45.60

-0.02 (-0.04%)

07:49
02/22/17
02/22
07:49
02/22/17
07:49
Initiation
Glaukos initiated  »

Glaukos initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Mar

DBD

Diebold

$29.70

-0.4 (-1.33%)

07:48
02/22/17
02/22
07:48
02/22/17
07:48
Initiation
Diebold initiated  »

Diebold initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Feb

FSLR

First Solar

$36.62

1.78 (5.11%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Downgrade
First Solar rating change  »

First Solar downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AET

Aetna

$126.34

1.07 (0.85%)

07:45
02/22/17
02/22
07:45
02/22/17
07:45
Hot Stocks
Aetna announces $3.3B accelerated share repurchase »

Aetna announced that it…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Conference/Events
CFA Society of Washington, D.C. to hold a luncheon discussion »

The CFA Society of…

CSCO

Cisco

$34.13

0.39 (1.16%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Cisco analyst commentary  »

Cisco at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 28

    Feb

  • 03

    Mar

M

Macy's

$32.29

-0.01 (-0.03%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Recommendations
Macy's analyst commentary  »

Macy's risk/reward…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NVDA

NVIDIA

$111.07

3.84 (3.58%)

07:43
02/22/17
02/22
07:43
02/22/17
07:43
Initiation
NVIDIA initiated  »

NVIDIA initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 05

    Mar

  • 16

    Mar

EYEG

EyeGate

$3.70

2.0601 (125.62%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Syndicate
Breaking Syndicate news story on EyeGate »

EyeGate files $3.29M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HCN

Welltower

$66.94

1.02 (1.55%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Hot Stocks
Welltower enters into strategic collaboration with Johns Hopkins Medicine »

Welltower announced a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 27

    Feb

  • 01

    Mar

HD

Home Depot

$145.02

2.02 (1.41%)

07:42
02/22/17
02/22
07:42
02/22/17
07:42
Recommendations
Home Depot analyst commentary  »

Home Depot guidance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Mar

AMD

AMD

$14.00

0.87 (6.63%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Initiation
AMD initiated  »

AMD initiated with a Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

, PLKI

Popeyes

$78.73

12.61 (19.07%)

07:41
02/22/17
02/22
07:41
02/22/17
07:41
Recommendations
Restaurant Brands, Popeyes analyst commentary  »

Oppenheimer sees…

QSR

Restaurant Brands

$57.60

3.7 (6.86%)

PLKI

Popeyes

$78.73

12.61 (19.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Feb

  • 23

    Mar

SBGI

Sinclair Broadcast

$36.90

0.4 (1.10%)

07:40
02/22/17
02/22
07:40
02/22/17
07:40
Hot Stocks
Sinclair Broadcast sees FY17 barter and trade revenue $116M »

Consensus for FY17 total…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Feb

  • 06

    Mar

CHS

Chico's

$14.29

0.27 (1.93%)

07:40
02/22/17
02/22
07:40
02/22/17
07:40
Hot Stocks
Chico's reports Q4 gross margin 35.5% vs. 34.4% a year ago »

When excluding Boston…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

ESPR

Esperion

$24.42

-0.58 (-2.32%)

07:40
02/22/17
02/22
07:40
02/22/17
07:40
Earnings
Breaking Earnings news story on Esperion »

Esperion reports Q4 EPS…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Feb

  • 23

    Feb

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.